Angion Biomedica Corp. (ANGN)
$1.00
$-8.80
(-89.80%)
As on 01-Jun-2023 16:00EDT
Market cap
$30 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-18 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
30,113,700
10 Years Aggregate
CFO
$-144.64 Mln
EBITDA
$-167.57 Mln
Net Profit
$-291.29 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Angion Biomedica (ANGN)
| -87.7 | -86.8 | -84.4 | -94.3 | -- | -- | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2022
|
|---|---|
|
Angion Biomedica (ANGN)
| -72.0 |
|
BSE Sensex
| 4.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Angion Biomedica (ANGN)
|
1.0 | 30.1 | 3.0 | -39.9 | -1,006.9 | -88.8 | -- | 0.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Angion Biomedica (ANGN)
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an... oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York. Read more
-
Pres, CEO & Chairman
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
-
Pres, CEO & Chairman
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
-
Headquarters
Uniondale, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Angion Biomedica (ANGN)
What is the current share price of Angion Biomedica Corp (ANGN) Today?
The share price of Angion Biomedica Corp (ANGN) is $1.00 (NASDAQ) as of 01-Jun-2023 16:00 EDT. Angion Biomedica Corp (ANGN) has given a return of -94.32% in the last 1 years.
What is the current PB & PE ratio of Angion Biomedica Corp (ANGN)?
Since, TTM earnings of Angion Biomedica Corp (ANGN) is negative, P/E ratio is not available.
The P/B ratio of Angion Biomedica Corp (ANGN) is 0.49 times as on 01-Jun-2023, a 91 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Angion Biomedica Corp (ANGN)?
The 52-week high and low of Angion Biomedica Corp (ANGN) are Rs -- and Rs -- as of 07-Sep-2026.
What is the market cap of Angion Biomedica Corp (ANGN)?
Angion Biomedica Corp (ANGN) has a market capitalisation of $ 30 Mln as on 01-Jun-2023. As per SEBI classification, it is a company.
Should I invest in Angion Biomedica Corp (ANGN)?
Before investing in Angion Biomedica Corp (ANGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.